Judith J Lok

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection
    Judith J Lok
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    AIDS 24:1867-76. 2010
  2. doi request reprint Impact of time to start treatment following infection with application to initiating HAART in HIV-positive patients
    Judith J Lok
    Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Building 2, 4th Floor, Boston, Massachusetts 02115, USA
    Biometrics 68:745-54. 2012
  3. doi request reprint Factors associated with remaining on initial randomized efavirenz-containing regimens
    Marlene Smurzynski
    aCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts bFred Hutchinson Cancer Research Center, Seattle, Washington cUniversity of Washington, Seattle, Washington dNorthwestern University Feinberg School of Medicine, Division of Infectious Diseases, Chicago, Illinois eBirmingham Veterans Affairs Medical Center and University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    AIDS 27:1887-97. 2013
  4. pmc No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Infect Dis 52:929-40. 2011

Detail Information

Publications4

  1. pmc Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection
    Judith J Lok
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    AIDS 24:1867-76. 2010
    ..We estimated the long-term CD4 cell count trajectory accounting for losses-to-follow-up and treatment discontinuations...
  2. doi request reprint Impact of time to start treatment following infection with application to initiating HAART in HIV-positive patients
    Judith J Lok
    Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Building 2, 4th Floor, Boston, Massachusetts 02115, USA
    Biometrics 68:745-54. 2012
    ..Results of fitting this model imply that early use of HAART substantially improves immune reconstitution in the early and acute phase of HIV-infection...
  3. doi request reprint Factors associated with remaining on initial randomized efavirenz-containing regimens
    Marlene Smurzynski
    aCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts bFred Hutchinson Cancer Research Center, Seattle, Washington cUniversity of Washington, Seattle, Washington dNorthwestern University Feinberg School of Medicine, Division of Infectious Diseases, Chicago, Illinois eBirmingham Veterans Affairs Medical Center and University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    AIDS 27:1887-97. 2013
    ..Efavirenz (EFV) along with two nucleoside reverse transcriptase inhibitors (NRTIs) is a recommended initial antiretroviral regimen. Understanding characteristics related to EFV success is clinically useful...
  4. pmc No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Infect Dis 52:929-40. 2011
    ....